CN116672358A - Composite preparation for human tissue - Google Patents
Composite preparation for human tissue Download PDFInfo
- Publication number
- CN116672358A CN116672358A CN202310379002.5A CN202310379002A CN116672358A CN 116672358 A CN116672358 A CN 116672358A CN 202310379002 A CN202310379002 A CN 202310379002A CN 116672358 A CN116672358 A CN 116672358A
- Authority
- CN
- China
- Prior art keywords
- benzoic acid
- chlorine
- bactericide
- lipid synthesis
- acid substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000002131 composite material Substances 0.000 title claims abstract description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000000460 chlorine Substances 0.000 claims abstract description 37
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 35
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 33
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 25
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 24
- 239000003899 bactericide agent Substances 0.000 claims abstract description 24
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 23
- 150000002632 lipids Chemical class 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 16
- 229940124091 Keratolytic Drugs 0.000 claims abstract description 13
- 230000001530 keratinolytic effect Effects 0.000 claims abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 abstract description 17
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 206010067197 Tinea manuum Diseases 0.000 abstract description 8
- 201000004647 tinea pedis Diseases 0.000 abstract description 6
- 206010005913 Body tinea Diseases 0.000 abstract description 5
- 208000002474 Tinea Diseases 0.000 abstract description 5
- 201000003875 tinea corporis Diseases 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 229920000832 Cutin Polymers 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 238000004299 exfoliation Methods 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 230000035984 keratolysis Effects 0.000 abstract 1
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 28
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 18
- 229910001919 chlorite Inorganic materials 0.000 description 17
- 229910052619 chlorite group Inorganic materials 0.000 description 17
- 239000004155 Chlorine dioxide Substances 0.000 description 14
- 235000019398 chlorine dioxide Nutrition 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 11
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 8
- 235000010234 sodium benzoate Nutrition 0.000 description 8
- 239000004299 sodium benzoate Substances 0.000 description 8
- 239000004342 Benzoyl peroxide Substances 0.000 description 7
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 7
- 235000019400 benzoyl peroxide Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000186427 Cutibacterium acnes Species 0.000 description 6
- 229940055019 propionibacterium acne Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 6
- 229960002218 sodium chlorite Drugs 0.000 description 6
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 6
- 206010000496 acne Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000005708 Sodium hypochlorite Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229940077239 chlorous acid Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical class NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- QSACCXVHEVWNMX-UHFFFAOYSA-N N-acetylanthranilic acid Chemical class CC(=O)NC1=CC=CC=C1C(O)=O QSACCXVHEVWNMX-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZALMZWWJQXBYQA-UHFFFAOYSA-N [N].[Cl] Chemical class [N].[Cl] ZALMZWWJQXBYQA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000005417 aminobenzoic acid derivatives Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000033785 sebaceous gland development Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a composite preparation for human tissue, which at least comprises a bactericide and a lipid synthesis inhibitor (or a keratolytic exfoliating agent), wherein the bactericide is selected from the group consisting of available chlorine bactericides, and the lipid synthesis inhibitor (or the keratolytic exfoliating agent) is selected from the group consisting of benzoic acid substances. When in use, the invention can realize the functions of sterilization and inhibition of lipid synthesis (or keratolysis and exfoliation), compared with the prior treatment technology, the dosage of the benzoic acid substances is controllable, and different concentrations can be set, so that the concentration of the benzoic acid substances can be reduced to reduce the stimulation to the skin when the seborrheic disease is treated, and the dosage of the bactericide can be properly increased to improve the sterilization efficiency; and can increase the consumption of benzoic acid substances to realize the functions of dissolving and exfoliating cutin for treating tinea corporis, tinea manus, tinea pedis and the like.
Description
Technical Field
The invention belongs to the technical field of clinical treatment preparations, and particularly relates to a compound preparation for human tissues.
Background
Seborrheic related diseases are relatively common in clinic, such as seborrheic dermatitis, acne and the like, and are related to lipid metabolism and excretion. Seborrheic dermatitis is a chronic skin inflammation that frequently occurs in the richer parts of sebaceous gland distribution, often spreading downwards from the head, and is typically damaged by dark yellow and red pimples or patches, with clear edges, and surfaces coated with greasy scales or crusts, with varying degrees of itching. The etiology of seborrheic dermatitis is not clear, and some researchers currently believe that seborrheic dermatitis is caused by dysregulation of normal flora on the skin surface and increased growth of malassezia on the basis of seborrhea. Acne is a chronic inflammatory skin disease of the pilosebaceous unit, and the occurrence of acne is closely related to the factors such as hypersecretion of sebum, blockage of the pilosebaceous ducts, bacterial infection, inflammatory reaction and the like. The level of androgens, particularly testosterone, in the human body is rapidly increased after the puberty is entered, sebaceous gland development is promoted, a large amount of sebum is produced, meanwhile, the abnormal keratinization of the pilosebaceous duct causes blockage of the duct, sebum discharge is blocked, and a cutin suppository, namely micro acne, is formed. A variety of microorganisms in hair follicles, particularly propionibacterium acnes, proliferate in large numbers, and lipase produced by propionibacterium acnes breaks down sebum to produce free fatty acids, while chemotactic inflammatory cells and mediators, ultimately inducing and aggravating inflammatory responses.
The principle of using external medicine for clinical treatment of diseases related to seborrheic is almost the same, namely, inhibition of lipid synthesis (or keratolytic exfoliation) and sterilization, but topical medicine: retinoids (vitamin a acid cream, adapalene gel, tazarotene gel) have potential teratogenic and photosensitivity risks; azelaic acid has the problems of higher required concentration, longer treatment time and poorer efficiency of killing the propionibacterium acnes; the sulfur lotion often causes the disadvantages of skin dryness, desquamation and the like; the treatment of benzoyl peroxide gel is relatively low in risk, and the pharmacological effects are as follows: after the benzoyl peroxide gel is externally used, the benzoyl peroxide gel is reduced by cysteine in epidermis keratin, and nascent active oxygen and benzoic acid are slowly released: slowly releases nascent oxygen, and can kill Propionibacterium acnes; the released benzoyl acid has antibacterial effect and lipid synthesis inhibiting effect on Propionibacterium acnes and the like, but the capability of benzoyl peroxide to release nascent oxygen and benzoic acid depends on the concentration of the benzoyl peroxide and the level of cysteine, high-concentration benzoyl peroxide can release more nascent oxygen and can generate excessive benzoic acid to stimulate skin, and low-concentration benzoyl peroxide can generate less nascent oxygen and benzoic acid, so that the propionibacterium acnes are weak in killing effect, and the dissolution of hair follicle keratosis is relatively slow, so that the treatment time is long.
In addition, tinea corporis and tinea manus are common diseases, and especially, the common antifungal drugs for the tinea manus and pedis with keratinization have poor curative effect because the drugs are difficult to penetrate through keratinization layers; and the sterilizing effect is poor by using a simple keratolytic exfoliant.
Disclosure of Invention
The invention aims to solve the technical problems that: aiming at the common defects of treating the diseases related to seborrheic diseases and tinea manus and tinea pedis, the compound preparation for human tissues is provided, and the compound preparation contains a bactericide and a lipid synthesis inhibitor (or a keratolytic exfoliating agent) and aims to solve the problem of using the lipid synthesis inhibitor and the concentration of the bactericide in the external preparation for treating the seborrheic diseases in the prior art, improve the treatment efficiency and shorten the treatment time for tinea corporis, tinea manus and tinea pedis exfoliating.
The preferred technical scheme adopted by the invention for solving the problems is as follows: a composite preparation for human tissue contains at least bactericide and lipid synthesis inhibitor (or keratolytic exfoliant); wherein the bactericide is one or more of available chlorine bactericides, and the lipid synthesis inhibitor (or keratolytic exfoliant) is one or more of benzoic acid substances.
For convenience of description, an example is as follows: sodium chlorite (NaClO) 2 ) Adding water to obtain sodium chlorite solution, adding sodium persulfate (Na 2 S 2 O 8 ) The reaction produced sodium sulfate (Na 2 SO 4 ) And chlorine dioxide (ClO) 2 ) Because chlorine dioxide is easily dissolved in water, chlorine dioxide solution is prepared after the reaction, sodium hypochlorite is added for fully stirring and dissolving, sodium benzoate is added for adjusting the PH value to 7, and the chlorous acid radical (ClO) containing solution is prepared 2- ) Hypochlorite (ClO) - ) Compound preparation of chlorine dioxide and sodium benzoate.
The bactericide is chlorine-containing bactericide, and has the characteristics of high sterilization efficiency and broad sterilization spectrum. The chlorine-containing bactericide contains available chlorine which can kill germs; the effective chlorine reflects the sterilizing capacity of the chlorine-containing bactericide, and the higher the effective chlorine is, the stronger the sterilizing capacity is, and the weaker the sterilizing capacity is otherwise. The effective chlorine sterilization has two action states: a. oxidizing and sterilizing: chlorine in the chlorine-containing bactericide is oxidation state chlorine. Oxidation state refers to the state in which the element appears at a higher valence, for chlorine the valence 0, +1, +3, +4, +5, +7 being the oxidation state chlorine. The oxidation state chlorine releases the oxidability in the oxidation-reduction reaction and is reduced into the reduction state chlorine with the valence of-1 to reach a natural stable state, and the reaction process can be used for sterilization, so that the oxidation state chlorine is effective chlorine capable of exerting effect; b. chloridizing sterilization: chlorine in the chlorine-containing bactericide is combined with proteins or lipids on bacteria to form nitrogen-chlorine compounds or chlorine-containing lipids, so that metabolism of cells is disturbed, and finally death of the bacteria is caused, and part of chlorine is also effective chlorine.
In the solution obtained by the above technical scheme, the chlorite (ClO) 2- ) The chlorine in the catalyst is positive trivalent cation chlorine (Cl) 3+ ) Is in a very unstable state, and can rapidly abstract the electrons of genetic materials and some enzyme substances in bacteria after entering the inside of the bacteria through the outer membrane of the bacteria, and return to anionic chloride (Cl) - ) Thereby achieving the aim of killing bacteria; hypochlorite (ClO) - ) The chlorine in the catalyst is positive monovalent cation chlorine (Cl) + ) Is also in a very unstable state, and rapidly takes electrons from genetic material and some enzyme substances in bacteria back to anionic chloride (Cl) after entering the bacteria through the outer membrane of the bacteria - ) Thereby achieving the aim of killing bacteria; chlorine dioxide (ClO) 2 ) Has good adsorptivity and permeability to cell wall, can effectively oxidize enzyme containing hydrophobic group in cell, can react with cysteine, tryptophan and free fatty acid, and can rapidly control synthesis of biological proteinThe permeability of the membrane is increased to kill bacteria. The chlorite, hypochlorite and chlorine dioxide in the compound preparation have synergistic sterilization effect, so that the sterilization effect is greatly improved, and the irritation of the solution to tissues is relatively small when the solution is close to neutral.
Benzoic acid species include: benzoic acid, benzoates and benzoic acid derivatives. Benzoate refers to the salt of benzoate with a metal ion. Benzoic acid derivatives include: aminobenzoic acid derivatives, fenamic acid derivatives, acetylaminobenzoic acid derivatives and diaminobenzoic acid derivatives.
Benzoic acid is insoluble in water at normal temperature, and in use, alcohol ether solvents are used for dissolving or sodium benzoate is used for replacing. The sodium benzoate has larger lipophilicity, is easy to penetrate a cell membrane to enter a cell body, can be reduced into benzoic acid under the condition of H+ ions, and has the effects of inhibiting the absorption of amino acid by the cell membrane, entering the cell body to ionize and acidify alkali storage in the cell, inhibiting the activity of a respiratory enzyme system of the cell, preventing acetyl coenzyme A condensation reaction and inhibiting the metabolism of the cell to influence lipid synthesis. The keratolytic stripping in the technical proposal is also established to inhibit the metabolism of cells when the concentration of benzoic acid substances is high, thereby leading to the dissolution and the shedding of the keratinized layer.
The lipid synthesis inhibitor in the technical proposal is different from the keratolytic exfoliating agent only in that the dosage of benzoic acid substances is different: when the consumption of benzoic acid substances is small, the benzoic acid substances can inhibit lipid synthesis to reduce skin oil secretion and dissolve the cuticle of the hair follicle opening, thereby controlling sebum metabolism of seborrheic diseases and playing a good role in treatment; when the dosage is larger, the external use liquid can be applied to tinea corporis, limbs or hands and feet, especially keratinized tinea manus and feet, can play a role in dissolving and exfoliating horny layer, and has better effect of treating fungi by matching with bactericides.
Since there are many types of chlorine-containing bactericides and many types of benzoic acid, benzoate and benzoic acid derivatives, various combinations of the compounds can be produced by using these materials to produce a composite preparation containing an effective chlorine bactericide and a lipid synthesis inhibitor (or keratolytic exfoliating agent), and the examples described in the foregoing technical schemes are only relatively easy to realize and representative, the scheme for obtaining the composite preparation of the present invention is not limited to the examples in the foregoing preferred technical schemes, and the claims are required as a basis.
When the compound preparation is applied to a required application position, the compound preparation can simultaneously realize the functions of sterilization and inhibition of lipid synthesis (or keratolytic stripping). Compared with the prior art, the invention has the advantages that the dosage of the p-benzoic acid substances is controllable, and different concentrations can be set, so that the concentration of the benzoic acid substances can be properly reduced to reduce the stimulation to the skin when the seborrheic disease is treated, and the dosage of the bactericide can be properly increased to improve the sterilization efficiency; and can increase the consumption of benzoic acid substances to realize the functions of dissolving and exfoliating cutin for treating tinea corporis, tinea manus, tinea pedis and the like.
Detailed Description
1. Formulations suitable for use in seborrheic disease: 1000ml of purified water was taken and 1020mg of sodium chlorite (NaClO 2 ) Adding into water to obtain sodium chlorite solution, slowly adding 1341mg sodium persulfate (Na) 2 S 2 O 8 ) And stirred to react to form sodium sulfate (Na 2 SO 4 ) And chlorine dioxide (ClO) 2 ) Because chlorine dioxide is easily dissolved in water, chlorine dioxide solution is prepared after the reaction, 210mg of sodium hypochlorite is added and stirred uniformly, the effective chlorine of the solution is about 300ppm, 25g of sodium benzoate is added again, and the pH value is regulated to 7 by dilute hydrochloric acid, thus obtaining the chlorous acid (ClO) 2- ) Hypochlorite (ClO) - ) Chlorine dioxide (ClO) 2 ) The available chlorine of sodium benzoate is 300 ppm.
2. The preparation is suitable for keratinized tinea manus and pedis: 1000ml of purified water was taken and 2040mg of sodium chlorite (NaClO 2 ) Adding into water to obtain sodium chlorite solution, slowly adding 2682mg sodium persulfate (Na 2 S 2 O 8 ) And stirred to react to form sodium sulfate (Na 2 SO 4 ) And chlorine dioxide (ClO) 2 ) Because chlorine dioxide is easily dissolved in water, chlorine dioxide solution is prepared after the reaction,adding 420mg of sodium hypochlorite, stirring, adding about 600ppm of sodium benzoate and 100g of dilute hydrochloric acid to adjust pH to 7 to obtain chlorite (ClO) 2- ) Hypochlorite (ClO) - ) Chlorine dioxide (ClO) 2 ) A complex formulation of sodium benzoate with an available chlorine of 600 ppm.
Claims (3)
1. A composite formulation for human tissue, characterized in that: the composite preparation at least contains bactericide and lipid synthesis inhibitor (or keratolytic exfoliant).
2. A composite preparation for human tissue according to claim 1, wherein: the bactericide is chlorine-containing bactericide, and comprises chlorine-containing bactericide which is sterilized by oxidation and chlorine-containing bactericide which is sterilized by chlorination.
3. A composite preparation for human tissue according to claim 1, wherein: the lipid synthesis inhibitor (or keratolytic exfoliating agent) is one or more of benzoic acid substances, wherein the benzoic acid substances comprise: benzoic acid, benzoates and benzoic acid derivatives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310379002.5A CN116672358A (en) | 2023-04-11 | 2023-04-11 | Composite preparation for human tissue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310379002.5A CN116672358A (en) | 2023-04-11 | 2023-04-11 | Composite preparation for human tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116672358A true CN116672358A (en) | 2023-09-01 |
Family
ID=87787894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310379002.5A Pending CN116672358A (en) | 2023-04-11 | 2023-04-11 | Composite preparation for human tissue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116672358A (en) |
-
2023
- 2023-04-11 CN CN202310379002.5A patent/CN116672358A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4788060A (en) | Multiple electrolyte douche and wipe composition | |
| US5958975A (en) | Antiodor, antimicrobial and preservative compositions and methods of using same | |
| US5616347A (en) | Chlorine dioxide skin medicating compositions for preventing irritation | |
| AU2003251547B2 (en) | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing | |
| US5407656A (en) | Method and compositions for the production of chlorine dioxide | |
| US20040156873A1 (en) | Topically Bioavailable Acne and Rosacea Treatment Compositions | |
| EP0654270B1 (en) | Preparation for the treatment of acne, seborrheic dermatitis and other skin diseases | |
| US20080014289A1 (en) | Vehicle and method for treating and preventing acne vulgaris and exfoliating the skin hypohalous acids | |
| CN109288691A (en) | A kind of graphene facial mask and preparation method thereof | |
| US20060188584A1 (en) | Composition and process for treating acne | |
| US20060269615A1 (en) | Topical treatment for skin irritation | |
| US20110236503A1 (en) | Topical Skincare Composition | |
| EP2592052A1 (en) | Anolyte, use of same and method for producing same | |
| US7955610B2 (en) | Antimicrobial composition for topical application and a method thereof | |
| CZ178196A3 (en) | Pharmaceutical preparation for papulopustular punctual therapy | |
| CN116672358A (en) | Composite preparation for human tissue | |
| US8932650B2 (en) | Multifunctional topical formulation for the treatment of acne vulgaris and other skin conditions | |
| CN113645955A (en) | Stable hypochlorous acid solution and its medical and cosmetic use | |
| JPH07267869A (en) | Remedy and method for medical treatment for dermatosis | |
| CA2926116C (en) | Wound treatment composition | |
| US20160051583A1 (en) | Method and composition for the treatment of skin conditions | |
| GB2486804A (en) | Antibacterial containing usnic acid/usnate and bismuth or copper salts | |
| RU2264220C2 (en) | Copper-silver ionator and curative agent with antimicrobic effect | |
| CA1176172A (en) | Pharmaceutical compounds for the treatment of acne and pharmaceutical compositions containing them | |
| US6054479A (en) | Preservative compositions and methods for using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |